Press Release BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC 15 hours ago
Press Release BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering Aug 6